FDA advisers review Pfizer’s COVID-19 vaccine for kids
By LAURAN NEERGAARD and MATTHEW PERRONE Associated Press WASHINGTON (AP) — U.S. health advisers are deliberating whether kid-size doses of Pfizer’s COVID-19 vaccine are safe and effective in young children. Tuesday’s meeting of the Food and Drug Administration panel is the first step toward expanding vaccinations to 28 million young children ages 5 to 11.
Continue Reading